The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | A long-term analysis of lenalidomide and rituximab for the treatment of CLL
Thomas Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, discusses the combination of lenalidomide and rituximab in the treatment of patients with chronic lymphocytic leukemia (CLL), and briefly comments on the findings of a long-term pooled analysis of two Phase II trials, CRC014 (NCT00628238) and CRC022 (NCT01199575), which investigated this therapeutic regimen. Results of the analysis suggest that this treatment approach results in a high overall response rate (ORR), which is greater than that seen with rituximab monotherapy, and confers a modest benefit to progression-free survival (PFS) and overall survival (OS), with tolerable long-term toxicity. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: California Institute for Regenerative Medicine (CIRM), Pharmacyclics/AbbVie, Oncternal Therapeutics, Inc., Breast Cancer Research Foundation, Genentech/Roche
Honoraria: Pharmacyclics/AbbVie, Dava Oncology, Curio Bioscience, Johnson & Johnson, Nexus Biopharma Inc., Janssen
Travel expenses: Pharmacyclics/AbbVie, Dava Oncology, Curio Bioscience, Johnson & Johnson, Nexus Biopharma Inc., Janssen
